Pathophysiology of hepatitis C virus infection and related liver disease

Trends in Microbiology

Volumn 12, Issue 2, 2004, Pages 96-102

  Pawlotsky, Jean Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASIALOGLYCOPROTEIN RECEPTOR; CD209 ANTIGEN; CD81 ANTIGEN; HYBRID PROTEIN; INTERFERON; L SIGN PROTEIN; LECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; POLYPROTEIN; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR; VIRUS RNA;

ANTIGEN PRESENTATION; APOPTOSIS; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL KILLING; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; ENDOCYTOSIS; FIBRIN FORMATION; GENE EXPRESSION; HEPATITIS C VIRUS; HOST CELL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTIOUS HEPATITIS; INTERNAL RIBOSOME ENTRY SITE; INTERNALIZATION; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PERSISTENT VIRUS INFECTION; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; STEATOSIS; T LYMPHOCYTE; TRANSCRIPTION INITIATION; ULTRACENTRIFUGATION; VIRION; VIRUS NUCLEOCAPSID; VIRUS PARTICLE; VIRUS REPLICATION;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0842303291     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2003.12.005     Document Type: Review

References (83)

1. National institutes of health consensus development conference statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 36:2002;S3-S20.
2. Penin, F. et al. Structural biology of hepatitis C virus. Hepatology (in press).
3. Thomssen R., et al. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. (Berl.). 182:1993;329-334.
4. Lindenbach B.D., Rice C.M. Flaviviridae: the viruses and their replication. Knipe D.M., Howley P.M. Fields Virology. Vol. 1:2001;991-1041 Lippincott Williams and Wilkins.
5. Op De Beeck A., et al. Biogenesis of hepatitis C virus envelope glycoproteins. J. Gen. Virol. 82:2001;2589-2595.
6. Penin F., et al. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75:2001;5703-5710.
7. Barth H., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:2003;41003-41012.
8. Agnello V., et al. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12766-12771.
9. Pileri P., et al. Binding of hepatitis C virus to CD81. Science. 282:1998;938-941.
10. Bartosch B., et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:2003;41624-41630.
11. Hsu M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7271-7276.
12. Scarselli E., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:2002;5017-5025.
13. Lozach P.Y., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278:2003;20358-20366.
14. Pohlmann S., et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77:2003;4070-4080.
15. Saunier B., et al. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J. Virol. 77:2003;546-559.
16. Tsukiyama-Kohara K., et al. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1992;1476-1483.
17. Spahn C.M., et al. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science. 291:2001;1959-1962.
18. Kieft J.S., et al. Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nat. Struct. Biol. 9:2002;370-374.
19. Grakoui A., et al. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1993;1385-1395.
20. Griffin S.D., et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 535:2003;34-38.
21. Pavlovic D., et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6104-6108.
22. Xu Z., et al. Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum. J. Virol. 77:2003;1578-1583.
23. Roussel J., et al. Characterization of the expression of the hepatitis C virus F protein. J. Gen. Virol. 84:2003;1751-1759.
24. Pawlotsky J.M., Germanidis G. The non-structural 5A protein of hepatitis C virus. J. Viral Hepat. 6:1999;343-356.
25. Katze M.G., et al. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2:2002;675-687.
26. Polyak S.J., et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75:2001;6095-6106.
27. Egger D., et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:2002;5974-5984.
28. Thimme R., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:2001;1395-1406.
29. Thimme R., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U. S. A. 99:2002;15661-15668.
30. Su A.I., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 99:2002;15669-15674.
31. Jinushi M., et al. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J. Immunol. 170:2003;1249-1256.
32. Tseng C.T., Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195:2002;43-49.
33. Crotta S., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195:2002;35-41.
34. Foy E., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 300:2003;1145-1148.
35. Blindenbacher A., et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology. 124:2003;1465-1475.
36. Farci P., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. U. S. A. 91:1994;7792-7796.
37. Shimizu Y.K., et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology. 223:1996;409-412.
38. Bartosch B., et al. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:2003;633-642.
39. Puntoriero G., et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17:1998;3521-3533.
40. Cerino A., et al. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J. Immunol. 167:2001;3878-3886.
41. Bertoletti A., Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 38:2003;4-13.
42. Bain C., et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology. 120:2001;512-524.
43. Fowler N.L., et al. Immune responses in hepatitis C virus infection: the role of dendritic cells. Immunol. Cell Biol. 81:2003;63-66.
44. Wedemeyer H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169:2002;3447-3458.
45. Appay V., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:2002;379-385.
46. Lechner F., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
47. Kittlesen D.J., et al. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 106:2000;1239-1249.
48. Chang K.M., et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100:1997;2376-2385.
49. Erickson A.L., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 15:2001;883-895.
50. Pawlotsky J.M. Molecular diagnosis of viral hepatitis. Gastroenterology. 122:2002;1554-1568.
51. Neumann A.U., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 282:1998;103-107.
52. Layden T.J., et al. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin. Liver Dis. 7:2003;163-178.
53. Poynard T., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 38:2003;75-85.
54. Perlemuter G., et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16:2002;185-194.
55. Barba G., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1200-1205.
56. Rubbia-Brandt L., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33:2000;106-115.
57. Serfaty L., et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 34:2001;428-434.
58. Castera L., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 52:2003;288-292.
59. Sulkowski M.S., Thomas D.L. Hepatitis C in the HIV-infected Person. Ann. Intern. Med. 138:2003;197-207.
60. Pol S., et al. HCV infection and hemodialysis. Semin. Nephrol. 22:2002;331-339.
61. Fiore G., et al. In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C. Eur. J. Gastroenterol. Hepatol. 9:1997;491-496.
62. Bertoletti A., et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology. 112:1997;193-199.
63. Napoli J., et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intra-hepatic expression of Th1-associated cytokines. Hepatology. 24:1996;759-765.
64. Piazzolla G., et al. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-alpha. J. Clin. Immunol. 20:2000;54-61.
65. Ando K., et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158:1997;5283-5291.
66. Kondo T., et al. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:1997;409-413.
67. Bedossa P., Paradis V. Approaches for treatment of liver fibrosis in chronic hepatitis C. Clin. Liver Dis. 7:2003;195-210.
68. Rockey D.C. Hepatic fibrogenesis and hepatitis C. Semin. Gastrointest. Dis. 11:2000;69-83.
69. Friedman S.L. Hepatic stellate cells. Prog. Liver Dis. 14:1996;101-130.
70. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275:2000;2247-2250.
71. Friedman S.L. Liver fibrosis - from bench to bedside. J. Hepatol. 38:(Suppl 1):2003;S38-S53.
72. Peters M.G., Terrault N.A. Alcohol use and hepatitis C. Hepatology. 36:2002;S220-S225.
73. Hezode C., et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment. Pharmacol. Ther. 17:2003;1031-1037.
74. Poynard T., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:2002;1303-1313.
75. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 36:2002;S74-S83.
76. Ray R.B., et al. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70:1996;4438-4443.
77. Ray R.B., et al. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology. 271:2000;197-204.
78. Sakamuro D., et al. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 69:1995;3893-3896.
79. Park J.S., et al. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem. Biophys. Res. Commun. 267:2000;581-587.
80. Ghosh A.K., et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J. Gen. Virol. 80:1999;1179-1183.
81. Moriya K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4:1998;1065-1067.
82. Lerat H., et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 122:2002;352-365.
83. Pietschmann T., Bartenschlager R. Tissue culture and animal models for hepatitis C virus. Clin. Liver Dis. 7:2003;23-43.